| Name | Title | Contact Details |
|---|
Community Health Center of Snohomish County (CHC) is a non-profit, Federally Qualified Community Health Center providing medical, dental, pharmacy, behavioral health, and additional ancillary services to nearly 70,000 individuals with 243,049 visits in 2021. For over 35 years, CHC has provided services to Snohomish County residents who face barriers to health care with the mission to provide our diverse community with access to high-quality, affordable primary health care. CHC operates seven medical primary care clinics, two medical walk-in clinics, six dental clinics, and five pharmacies, located in convenient locations in Arlington, Edmonds, Everett, and Lynnwood.
Towson Medical Equipment Co is a Towson, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RTI Laboratories, Inc. is a Livonia, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Priority Life Care, a family-owned company, was built on the thought that every senior deserves quality care regardless of their economic background. With over a decade of experience, the family has been a pioneer in the industry giving a win-win solution for both seniors and coworkers (the #PLCfamily). Our focus on senior living includes independent living, assisted living, and memory care. The key to our approach is in our purpose of supporting independence. In addition to care, our residents are able to continue living out their lives with healthy choices tailored to their individual needs.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.